Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NHP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNHP discloses unsolicited mini-tender offer at $7.27/share, 47% below market; Board neutral
Filed June 16, 2026 · Period ending June 15, 2026 · ~1 min read
Key Changes
-
high
MacKenzie Capital launched unsolicited mini-tender offer for 150,000 shares (0.2% of outstanding) at $7.27/share, approximately 47.2% below the June 15 Nasdaq closing price of $13.78/share.
Item 8.01 — Other Events verify on EDGAR → -
high
Board remains neutral after consulting advisors, makes no recommendation on whether shareholders should tender. None of NHP's directors, officers, or affiliates intend to tender their shares.
Exhibit 99.1 view on EDGAR → -
medium
Shareholders tendering would forfeit distribution rights after March 31, 2026, and the $7.27 offer price would be reduced by any future cash distributions NHP declares.
Exhibit 99.1 view on EDGAR → -
medium
Alternative liquidity options exist: secondary auction trades in April-May 2026 ranged from $8.41-$11.41/share, approximately 13.6%-36.3% above MacKenzie's offer price.
Exhibit 99.1 view on EDGAR → -
medium
Mini-tender offers target less than 5% of shares and fall below SEC tender offer disclosure and procedural protections that apply to larger offers.
Item 8.01 — Other Events verify on EDGAR →
Summary
National Healthcare Properties disclosed an unsolicited mini-tender offer from MacKenzie Capital to purchase up to 150,000 shares at $7.27 per share—a 47.2% discount to the June 15 Nasdaq closing price of $13.78. The Board evaluated the offer with outside advisors and decided to remain neutral, making no recommendation to shareholders.
Notably, no company insiders intend to tender their shares, and MacKenzie itself acknowledged in its offer materials that recent secondary auction trades occurred at prices 13.6% to 36.3% higher than its bid. Retail holders should understand that mini-tender offers target less than 5% of shares outstanding and therefore avoid the SEC disclosure and procedural protections that govern larger tender offers.
Shareholders who tender would forfeit distribution rights after March 31, 2026, and the offer price would be reduced by any future cash distributions NHP declares. The Board's neutrality and insider non-participation suggest the offer is not compelling relative to holding shares or pursuing alternative liquidity channels. This is a disclosure event with no operational impact on NHP's business.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
After careful evaluation of the MacKenzie Offer, the Company determined (i) not to make any recommendation and (ii) to remain neutral as to whether stockholders should tender their shares of the Company’s common stock in the MacKenzie Offer.
NHP evaluated the offer and decided to remain neutral, making no recommendation to shareholders on whether to tender their shares. The company published a letter to stockholders on June 16, 2026 notifying them of this neutral stance.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
NHP stockholders seeking immediate liquidity may have other options, including secondary auction trades, which MacKenzie points out may result in a higher sales price, with MacKenzie noting that for the period between April to May 2026, “…the Shares reported by CTT Auctions were $8.41-$11.41 per Share [with respect to common stock]”, which represent actual sales of NHP common stock at prices that are approximately 13.6%-36.3% higher than the MacKenzie Offer Price.
The Board disclosed that stockholders seeking immediate liquidity have alternative options, including secondary auction trades. MacKenzie itself noted that actual sales of NHP common stock through CTT Auctions during April to May 2026 ranged from $8.41 to $11.41 per share, representing prices approximately 13.6% to 36.3% higher than MacKenzie's $7.27 offer price. The Board also noted that there is currently no active share repurchase plan for common stock until the Class A Conversion on October 19, 2026.
Added in current filing · view on EDGAR →
However, stockholders who tender their shares pursuant to the MacKenzie Offer would give up their rights to any future distributions after March 31, 2026. ... Pursuant to the MacKenzie Offer, the MacKenzie Offer Price will be reduced by any cash distributions made to stockholders by NHP after March 31, 2026. Any such distribution will be assigned to MacKenzie as a condition to the MacKenzie Offer.
Stockholders who tender their shares to MacKenzie would forfeit their rights to any future distributions after March 31, 2026. Additionally, the MacKenzie offer price of $7.27 per share will be reduced by any cash distributions NHP makes to stockholders after March 31, 2026, with such distributions assigned to MacKenzie as a condition of the offer. NHP anticipates making quarterly cash distributions subject to Board approval, though there is no guarantee of future distributions.
Added in current filing · view on EDGAR →
None of NHP’s directors, executive officers, affiliates or subsidiaries intend to tender their shares of common stock to MacKenzie.
NHP disclosed that none of its directors, executive officers, affiliates, or subsidiaries intend to tender their shares of common stock to MacKenzie. This signals that company insiders do not view the offer as attractive relative to holding their shares.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 13, 2026 · How we verify